Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Silver North Intersects 1.83 metres True Width of 1,088 g/t Silver, 3.90 g/t Gold (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Lexaria Bioscience Corp LEXX

Alternate Symbol(s):  LEXXW

Healthcare
Lexaria Bioscience Corp. is a Canada-based biotechnology company. The Company is engaged in pursuing the enhancement of the bioavailability of a diverse and a range of active pharmaceutical ingredients (API) using DehydraTECH, its patented proprietary drug delivery technology. The Company’s patented drug delivery technology, DehydraTECH, is designed to improve the way active molecules enter the... see more

NDAQ:LEXX - Post Discussion

Lexaria Bioscience Corp > Lexaria Bioscience Corp. (NASDAQ: LEXX) - A Zacks Update
View:
Post by whytestocks on Jul 11, 2023 9:00pm

Lexaria Bioscience Corp. (NASDAQ: LEXX) - A Zacks Update

Just In: $LEXX Lexaria Bioscience Corp. (NASDAQ: LEXX) - A Zacks UpdateLexaria just released its mid-year update, highlighting its key milestones so far and its objectives going forward, summarized in a recent Zacks update Of note was the company’s most ambitious clinical study yet, HYPER-H21-4, along with its growing patent portfolio that now sees six addi...LEXX - Lexaria Bioscience Corp. (NASDAQ: LEXX) - A Zacks Update
Comment by lscfa on Jul 11, 2023 11:52pm
$12 US fair value.... https://s27.q4cdn.com/906368049/files/News/2023/Zacks_SCR_Research_06262023_LEXX_Vandermosten.pdf
Comment by ranman on Nov 23, 2023 5:12pm
Should do better than $12.00 if the new wt loss drug can make it into our stable of pharmaceuticals. Novo Nordisk shares rise as Wegovy shows heart benefits beyond weight loss weight control
Lexaria Bioscience Corp